AstraZeneca Results Presentation Deck
Core profit and loss
Total revenue
- product sales
- collaboration revenue
Gross margin
Operating expenses ¹
- R&D expenses
- SG&A expenses
Other operating income
Operating profit
Tax rate
EPS
Impact of pandemic vaccine on EPS
YTD 2021
$m
25,406
25,043
363
74.1%
13,649
5,591
7,736
1,346
6,610
16.8%
$3.59
($0.03)
change
%
28
29
10
(5.8) pp
20
30
14
50
23
23
% total
revenue
100
99
1
54
22
30
5
26
Q3 2021
$m
9,866
9,741
125
74.5%
5,138
2,152
2,866
37
2,281
21.6%
$1.08
$0.01
11 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales.
1. Includes distribution expenses. R&D = research and development; SG&A= sales, general and administration; pp = percentage points; n/m = growth rate not meaningful.
change
%
48
47
115
(4.7) pp
35
46
29
(87)
28
15
% total
revenue
100
99
1
52
22
29
I
23
4View entire presentation